GERMANY— Beiersdorf, a Germany-based skincare company, has announced a multi-year partnership with Macro Biologics, Inc., aiming to collaborate on developing biodegradable antimicrobial peptides with broad applications in skincare and healthcare.
As part of this strategic alliance, Beiersdorf has also invested in Macro Biologics through its Oscar & Paul Corporate Venture Capital Unit, signaling a significant commitment to innovation and sustainability.
By integrating Macro Biologics’ cutting-edge technology in antimicrobial research into the skincare and healthcare sectors, Beiersdorf reinforces its dedication to delivering transformative and sustainable innovations to its consumers.
The collaboration will focus on leveraging Macro Biologics’ highly effective antimicrobial peptides, known as “Amicidins,” to develop Beiersdorf’s new products and formulas.
These Amicidins are designed to combat a wide range of bacteria, making them particularly valuable in improving or alleviating various skin conditions.
Additionally, they are formulated for early, localized application to prevent wound infections, thereby offering significant potential in both skincare and healthcare settings.
The joint objective of this partnership is to create highly effective, safe, and sustainable solutions across Beiersdorf’s diverse brand portfolio, with a primary focus on dermatological skincare and healthcare.
While expressing her enthusiasm for this collaboration, Dr Gitta Neufang, Corporate Senior Vice President of Global R&D at Beiersdorf, highlighted that it aligns perfectly with Beiersdorf’s ‘Win with Care’ strategy and their ambition to lead in Climate Care.
Dr. Neufang emphasized the importance of finding a partner like Macro Biologics, which shares Beiersdorf’s visionary approach to innovation in the field of antimicrobial peptides.
She noted that the company is eager to bring Macro Biologics’ advanced technology into the skincare and healthcare realms.
For his part, Dr Michael Bevilacqua, CEO and CSO of Macro Biologics, echoed this sentiment, stating that they are thrilled to partner with Beiersdorf, a global leader in skincare and healthcare.
He pointed out that the collaboration is an excellent fit from both research and business perspectives.
Beiersdorf’s deep expertise in product formulation, development, and commercialization will empower Amicidins to significantly improve lives in various settings.
Dr. Bevilacqua added that the partnership is grounded in shared values, as both companies strive to create sustainable value for people and the environment.
Beiersdorf’s new Serum Reverses Skin Aging with Epigenetic Technology
This partnership coincides with the recent launch of Beiersdorf’s innovative Eucerin Hyaluron-Filler Epigenetic Serum, which allows consumers to experience the impactful results of Beiersdorf’s epigenetic research.
This new product features Beiersdorf’s patented skin-specific age clock technology, an algorithm based on epigenetic patterns that measures skin’s biological age.
These insights have been crucial for Beiersdorf scientists, leading to identifying the active ingredient Epicelline®, which can turn back the age clock of skin cells and reverse signs of aging.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE
